Bozic Carmen's Insider Trades & SAST Disclosures
Bozic Carmen's most recent trade in Vertex Pharmaceuticals, Inc. was a trade of 4,962 Common Stock done at an average price of $479.6 . Disclosure was reported to the exchange on Feb. 26, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Bozic Carmen.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 479.61 per share. | 26 Feb 2025 | 4,962 | 32,669 (0%) | 0% | 479.6 | 2,379,825 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 483.28 per share. | 24 Feb 2025 | 3,310 | 37,631 (0%) | 0% | 483.3 | 1,599,657 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 463.46 per share. | 14 Feb 2025 | 1,912 | 40,941 (0%) | 0% | 463.5 | 886,136 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 5,546 | 42,853 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 467.98 per share. | 10 Feb 2025 | 2,142 | 37,307 (0%) | 0% | 468.0 | 1,002,413 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 10,262 | 33,521 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 5,928 | 39,449 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Sale of securities on an exchange or to another person at price $ 476.75 per share. | 07 Aug 2024 | 2,280 | 23,259 (0%) | 0% | 476.8 | 1,086,990 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Sale of securities on an exchange or to another person at price $ 488.46 per share. | 24 Jul 2024 | 2,280 | 25,539 (0%) | 0% | 488.5 | 1,113,689 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Sale of securities on an exchange or to another person at price $ 487.34 per share. | 10 Jul 2024 | 2,280 | 27,819 (0%) | 0% | 487.3 | 1,111,135 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Sale of securities on an exchange or to another person at price $ 471.72 per share. | 26 Jun 2024 | 2,280 | 30,099 (0%) | 0% | 471.7 | 1,075,522 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Sale of securities on an exchange or to another person at price $ 478.00 per share. | 12 Jun 2024 | 2,280 | 32,379 (0%) | 0% | 478 | 1,089,840 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Sale of securities on an exchange or to another person at price $ 445.56 per share. | 29 May 2024 | 2,280 | 34,659 (0%) | 0% | 445.6 | 1,015,877 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Bozic Carmen | EVP and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 431.79 per share. | 23 Feb 2024 | 3,309 | 36,939 (0%) | 0% | 431.8 | 1,428,793 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Bozic Carmen | EVP and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 424.01 per share. | 16 Feb 2024 | 3,750 | 43,060 (0%) | 0% | 424.0 | 1,590,038 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Bozic Carmen | EVP and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 420.58 per share. | 16 Feb 2024 | 2,812 | 40,248 (0%) | 0% | 420.6 | 1,182,671 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Bozic Carmen | EVP and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 422.74 per share. | 09 Feb 2024 | 2,100 | 46,810 (0%) | 0% | 422.7 | 887,754 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Bozic Carmen | EVP and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 7,866 | 42,982 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 5,928 | 48,910 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 5,814 | 35,116 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 289.12 per share. | 24 Feb 2023 | 3,308 | 63,207 (0%) | 0% | 289.1 | 956,409 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 292.85 per share. | 17 Feb 2023 | 3,750 | 66,515 (0%) | 0% | 292.9 | 1,098,188 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 298.26 per share. | 10 Feb 2023 | 4,992 | 70,265 (0%) | 0% | 298.3 | 1,488,914 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 294.33 per share. | 10 Feb 2023 | 2,707 | 75,257 (0%) | 0% | 294.3 | 796,751 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 10,324 | 59,836 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 10,262 | 70,098 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 7,866 | 77,964 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 271.24 per share. | 31 May 2022 | 311 | 49,512 (0%) | 0% | 271.2 | 84,356 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 227.86 per share. | 24 Feb 2022 | 1,242 | 49,823 (0%) | 0% | 227.9 | 283,002 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 232.51 per share. | 17 Feb 2022 | 3,439 | 51,065 (0%) | 0% | 232.5 | 799,602 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 237.74 per share. | 10 Feb 2022 | 2,437 | 54,504 (0%) | 0% | 237.7 | 579,372 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 11,628 | 46,679 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 10,262 | 56,941 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 2,098 | 35,051 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 210.04 per share. | 28 May 2021 | 311 | 32,953 (0%) | 0% | 210.0 | 65,322 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 217.57 per share. | 24 Feb 2021 | 311 | 33,264 (0%) | 0% | 217.6 | 67,664 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 214.16 per share. | 10 Feb 2021 | 2,367 | 33,575 (0%) | 0% | 214.2 | 506,917 | Common Stock |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 11,627 | 35,942 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 10,324 | 24,315 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharmaceuticals, Inc. | Carmen Bozic | EVP and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 282.74 per share. | 29 May 2020 | 311 | 13,991 (0%) | 0% | 282.7 | 87,932 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges